Breaking News
April 19, 2019 - Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
April 19, 2019 - Exercise can improve non-motor symptoms of Parkinson’s disease
April 19, 2019 - KZFPs play a key role in the regulation of human genome
April 19, 2019 - Extracts of ginkgo seeds show antibacterial activity on pathogens that cause skin infections
April 19, 2019 - Exercises and swimming goggles may reduce adverse effects on eye during long spaceflights
April 19, 2019 - Review suggests a reciprocal relationship between obesity and self-control
April 19, 2019 - Study identifies how enterococci bacteria cause antibiotic-resistant bloodstream infections
April 19, 2019 - Triple negative breast cancer develop resistance to chemotherapy by turning on molecular pathway
April 19, 2019 - Researchers identify key clues to brain and pancreas development
April 19, 2019 - Metformin May Cut Risk for Prematurity, Miscarriage in PCOS
April 19, 2019 - Obese mouse mothers trigger heart problems in offspring
April 19, 2019 - Research sheds light on how leukemia cells become resistant to drugs
April 19, 2019 - Health Tip: Stopping Nosebleeds – Drugs.com MedNews
April 19, 2019 - Pediatric endocrinologist gives iconic ‘Mona Lisa’ a second medical opinion
April 19, 2019 - Tapping patients’ wisdom for C-section pain management
April 18, 2019 - Why have autism rates ‘exploded’ in New Jersey?
April 18, 2019 - Microbiome science may help doctors to improve treatment for children with IBS
April 18, 2019 - New gene therapy cures babies with fatal ‘Bubble Boy’ disease
April 18, 2019 - No female mice? Scientists may still approve NIH grant
April 18, 2019 - What needs to be said about mental health in medicine
April 18, 2019 - Hickenlooper Expanded Medicaid, Created State-Run Marketplace To Insure Nearly All Coloradans
April 18, 2019 - Cancer cells grown in tumor-mimicking environment can help predict the effect of experimental drugs
April 18, 2019 - Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
April 18, 2019 - Adhesive gel bonds to eye surface, could repair injuries without surgery
April 18, 2019 - The future of genomics: A podcast featuring Stanford geneticists
April 18, 2019 - As Syphilis Invades Rural America, A Fraying Health Safety Net Is Failing To Stop It
April 18, 2019 - APOE gene impacts sleep depending on gender and severity of Alzheimer’s
April 18, 2019 - PCORI’s newly approved awards focus on cancer pain and opioid use disorders
April 18, 2019 - New tool provides a standard way to measure effects of caring for survivors of TBI
April 18, 2019 - Smartphone use risks eye examination misdiagnosis
April 18, 2019 - How drug-resistant bugs grow in CF patients’ lungs
April 18, 2019 - Gordana Vunjak-Novakovic Elected to American Academy of Arts & Sciences
April 18, 2019 - Podcast: KHN’s ‘What The Health?’ You Have Questions, We Have Answers
April 18, 2019 - Diabetic drug shows potential to be repurposed as heart disease treatment for non-diabetic patients
April 18, 2019 - New estimation method assesses natural variations in sex ratio at birth
April 18, 2019 - UTA scientist receives $1.17 million grant for cancer research
April 18, 2019 - Coagulation factor VIIa prevents bleeds in hemophilia animal models
April 18, 2019 - Researchers identify risk factors for severe infection after knee replacement
April 18, 2019 - Mass drug administration can offer community-level protection against malaria
April 18, 2019 - FDA’s added sugar label could have substantial health and cost-saving benefits
April 18, 2019 - Researchers identify cause of inherited metabolic disorder
April 18, 2019 - Single strip of white paint not sufficient to protect people who ride bikes
April 18, 2019 - Partner status influences link between sexual problems and self-efficacy in breast cancer survivors
April 18, 2019 - Colorectal Neoplasia Risk Up for Hodgkin Lymphoma Survivors
April 18, 2019 - Rigid spine muscular dystrophy – Genetics Home Reference
April 18, 2019 - Simple bile acid blood test could tell risk of stillbirth
April 18, 2019 - Center for Experimental Therapeutics aims to enable all steps of drug development | News Center
April 18, 2019 - Falling for telephone scams could be an early sign of dementia
April 18, 2019 - Researchers annotate key neuronal proteins in lamprey genome
April 18, 2019 - Study uncovers new biomarker for personalized cancer treatments
April 18, 2019 - Scientists enter research collaboration to find a cure for cancer
April 18, 2019 - Study to compare benefits of tai chi and mindfulness meditation on MS symptoms
April 18, 2019 - Gestational diabetes during pregnancy may increase risk of type 1 diabetes in children
April 18, 2019 - Maternal age has no effect on IVF success, conclude researchers
April 18, 2019 - Is a New Remedy for Body Odor on the Horizon?
April 18, 2019 - Orthostatic hypotension – Genetics Home Reference
April 18, 2019 - Healing the heartbreak of stillbirth and newborn death
April 18, 2019 - New study calls healthiness of eggs into question
April 18, 2019 - Conference to highlight advances in human immune monitoring, bioinformatics | News Center
April 18, 2019 - Bacteria use viruses for self-recognition, study reveals
April 18, 2019 - New adhesive patch could help reduce post-heart attack muscle damage
April 18, 2019 - Researchers analyze the effects of dark play in a serious video game
April 18, 2019 - Scientists revive pig brain cells four hours after death
April 18, 2019 - Filial cannibalism and offspring abandonment may be forms of parental care
April 18, 2019 - Two proteins act in concert to maintain a healthy heart in mice, shows study
April 18, 2019 - Scientists create a functioning 3D printed heart
April 18, 2019 - Non-invasive vagus nerve stimulation improves disease symptoms in patients with rheumatoid arthritis
April 18, 2019 - Majority of men struggle to understand diagnosis and treatment of prostate cancer
April 18, 2019 - Researchers create new small molecules that may combat equine encephalitis viruses
April 18, 2019 - Animal-assisted therapy improves social behavior in patients with brain injuries
April 18, 2019 - Some viruses help protect harmful bacteria in CF patients | News Center
April 18, 2019 - Outpatient healthcare providers inappropriately prescribe antibiotics to 40% of patients
April 18, 2019 - Men who have a resting heart rate of 75 bpm are twice as likely to die early
April 18, 2019 - Novel serum biomarkers to detect NAFLD-related fibrosis
April 18, 2019 - New study delves deeper into individual genomic differences than ever before
April 18, 2019 - Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
April 18, 2019 - Emotional mirror neurons found in rats
April 18, 2019 - Sylvia Plevritis appointed chair of biomedical data science | News Center
April 18, 2019 - Cervical cancer subtype increasing in several subpopulations of women
April 18, 2019 - Yeast strain provides manufacturing boost to low-calorie sweetener derived from lactose
More Alzheimer’s Drug Trial Failures: Are Researchers on the Wrong Track?

More Alzheimer’s Drug Trial Failures: Are Researchers on the Wrong Track?

image_pdfDownload PDFimage_print

WEDNESDAY, April 10, 2019 — Amyloid beta has long been a prime suspect in Alzheimer’s disease, since abnormal levels of the protein form disruptive plaques between patients’ brain cells.

But drug trials aimed at lowering amyloid levels have repeatedly failed to save people’s brains, and some researchers now believe the focus needs to shift to other potential culprits.

Researchers pulled the plug early on the latest failed clinical trial, after patients’ brain power continued to decline even though the amyloid beta blocker verubecestat successfully lowered amyloid levels in their brains and spinal fluid.

The disappointing verubecestat results appear in the April 11 issue of the New England Journal of Medicine, alongside a research letter announcing similarly negative preliminary findings from the clinical trial of another amyloid blocker called atabecestat.

These negative results jibe with those of earlier trials, and present “pretty strong evidence that amyloid-lowering is the wrong target,” said Dr. David Knopman. He’s a professor of neurology with the Mayo Clinic who wrote an editorial accompanying the new reports.

Knopman noted that the verubecestat trial showed that amyloid levels declined slightly in the brain and fairly substantially in the spinal fluid following treatment with the drug, but patients’ brain structure wizened and their ability to reason and remember still declined.

“They hit the target and yet people got worse, consistently worse, both in terms of brain structure and brain cognition,” Knopman said.

The odd thing is that amyloid beta plaques remain a “very good marker of Alzheimer’s-related cognitive impairment,” Knopman said. When these plaques are found, it’s very likely the person is suffering from Alzheimer’s.

Because of this, it’s very important that research focused on amyloid beta continues, said Rebecca Edelmayer, director of scientific engagement at the Alzheimer’s Association.

“There’s still a preponderance of evidence that amyloid beta is a hallmark protein of the disease, and I think we need to continue to understand the role it plays in the disease,” said Edelmayer, who wasn’t involved with the studies.

“The trials that are still underway looking at part of the amyloid signaling cascade need to be completed so we can learn from each of these trials, whether there are positive or negative results,” she said.

At the same time, the Alzheimer’s Association has already broadened the scope of its research funding to focus on other means by which the disease could be treated or prevented, Edelmayer said.

Amyloid clinical trial results are all popping up now because, as one of Alzheimer’s key symptoms, amyloid beta plaques were one of the first therapeutic targets to be pursued, she said.

“It makes sense we’re seeing amyloid in the news most frequently because these are the ideas that were started 10 to 15 to 20 years ago,” which is about as long as it takes for science to fully explore such avenues, Edelmayer said.

In the intervening years, many other processes and potential treatment targets have started to be pursued in the quest for a cure.

Research teams still are investigating the role of the other major hallmark of Alzheimer’s disease: the tangles of tau proteins that collect within neurons and potentially harm communication between synapses.

“We know these two hallmarks of the disease are present and helping us define some of those clinical symptoms, but we don’t yet know why these healthy proteins in our brain turn to something that becomes aberrant or pathological or destructive in the brain,” Edelmayer said.

Other treatment targets being investigated include chronic inflammation in the brain, the health of cerebral blood vessels, the role of the immune system and the contribution of genetics, Edelmayer and Knopman said.

“There’s a huge diversity of therapeutic mechanisms that are being looked at,” Knopman said. “We will leave no stone unturned when it comes to this disease.”

Some researchers are also advancing theories by which viruses or bacteria might be the culprit.

A study presented last week at the annual meeting of the American Association of Anatomists argued that the bacteria P. gingivalis, which causes gum disease, could be associated with Alzheimer’s. Other earlier research has drawn a similar potential link to the herpes simplex virus.

The “infection” theory of Alzheimer’s is still in its infancy, however, Knopman noted.

“I do not believe the evidence provides any avenues at this point for treatment other than the obvious sledgehammer of giving antivirals to Alzheimer’s patients, which is hardly justified based on the slimness of the data,” Knopman said.

The verubecestat trial ended in February 2018, a year prior to completion of its first phase, after 1,454 patients had been enrolled, the new report says. A data and safety monitoring committee concluded that the drug would not outperform a placebo at either of two doses being tested.

The atabecestat trial also ended early, in May 2018, due to adverse events related to liver health. The 557 participants are still being tracked as part of a safety follow-up.

More information

The Mayo Clinic has more about brain changes related to Alzheimer’s.

© 2019 HealthDay. All rights reserved.

Posted: April 2019

Tagged with:

About author

Related Articles